Canterbury DHB


Response Assessment

Monitor the patient's response to therapy by following blood counts and assessing symptoms and signs of disease i.e. periodic clinical evaluation and monitoring of complete blood count, guided by the patient's clinical status and the nature of their treatment.

There is no need to routinely monitor bone marrow or molecular response, unless there is a change in the patient's clinical symptoms or blood picture that is suspicious for transformation, fibrosis etc.

About this Canterbury DHB document (536184):

Document Owner:

Bridgett McDiarmid (see Who's Who)

Last Reviewed:

August 2018

Next Review:

April 2021


Note: Only the electronic version is controlled. Once printed, this is no longer a controlled document. Disclaimer

Topic Code: 536184